Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharma and Lupin receive US FDA approval for divalproex tablets

This article was originally published in Scrip

Executive Summary

Sun Pharmaceutical Industriesand Lupin's US subsidiary have received final approval from the US FDAfor their respective ANDAs for divalproex sodium delayed-release tablets 125mg, 250mg and 500mg, generic versions of Abbott Laboratories' Depakote tablets. Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches. Both companies expect their products to be on the market shortly. The three strengths of Depakote delayed release tablets reported annual sales of about $750 million in the US.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel